Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Other Non Operating Income (2020 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Other Non Operating Income for 6 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non Operating Income changed N/A to $1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $92.6 million, a 1152.39% increase, with the full-year FY2024 number at $3.8 million, down 38.93% from a year prior.
  • Other Non Operating Income was $1.8 million for Q3 2025 at Whitehawk Therapeutics, up from -$3000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $88.2 million in Q1 2025 to a low of -$1.4 million in Q1 2021.
  • A 5-year average of $7.2 million and a median of $1.5 million in 2023 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: crashed 100.06% in 2024, then soared 7114.55% in 2025.
  • Whitehawk Therapeutics' Other Non Operating Income stood at $933000.0 in 2021, then soared by 76.74% to $1.6 million in 2022, then soared by 274.23% to $6.2 million in 2023, then crashed by 58.74% to $2.5 million in 2024, then fell by 29.3% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Other Non Operating Income are $1.8 million (Q3 2025), -$3000.0 (Q2 2025), and $88.2 million (Q1 2025).